Teva/Sanofi’s Phase IIb Data In IBD Look Competitive Vs. Merck, Roche
Teva reported Phase IIb data for its anti-TL1A agent in ulcerative colitis and Crohn’s that the company called transformational and analysts deemed potentially best in class.
Teva reported Phase IIb data for its anti-TL1A agent in ulcerative colitis and Crohn’s that the company called transformational and analysts deemed potentially best in class.